Forums. Initial FDA and EMA Advice on Presendin Development, page-3. Created with Sketch. Latest Posts. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. Advertise on HotCopper. ASX - By Stock. INVEX THERAPEUTICS LTD (ASX:IXC) - IXC chart, page-9 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum Forums ASX - By Stock IXC. Market . ASX - Day Trading. 1950. Mernova, a subsidiary of Melodiol Global Health (ASX:ME1), is on track to achieve its highest ever monthly sales, with revenues expected to reach A$891,944 in October 2023. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-4. AX stock on Yahoo Finance. 79 -0. ASX - Day TradingInvex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. I'm thinking of flying there myself!Prof Alex Sinclair is to present in Melbourne and Sydney next. Created with Sketch. Share Appreciate the commentary and post. . Transparency is our policy. ASX - Day Trading. 30 to $15 in the space of 1 and half years Bios move fast when value is recognised. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. Discover historical prices for IXC. We are a team of expert financial advisers each specialising in different, yet complementary areas. ASX - Day Trading. ASX - By Stock. Created with Sketch. Given that IXC's Chief Scientific Officer, Alex Sinclair, is the author of IIH treatment guidelines, the introduction of an effective medication to the market would likely lead to a rapid integration of Presendin into treatment protocols. Created with Sketch. ASX - General. IXC current EV is close to $0 so again Im not sure what OSL valuation is but I dont think it stacks up as good as IXC and where IXC is at in its timeline. Umbrella Society is a proud Living Wage Employer! Greater Victoria's official living wage has been adjusted to $25. Share No great change in the top 2 big boys who hold 17% of the company, Twiggy's fund unchanged. Market . IXC Valuation Report MST. . Share I've got no issues with it. 20. 5¢ Sentiment: Hold Disclosure: Held IXC Valuation Report MST. Forums. 0% $ODM 35. 0. . It seems a massive hole within the industry of treatment *cough cough* IXC Also surprised by the amount of activity and people who have the disease. ASX - Day Trading It is certainly an interesting case study regarding management strategy; that noted strategy would work during fair or bullish markets as participants are acting rationally (and by sticking to their knitting during Covid Crash the IXC share price bounced back heavily with Phase II results - so perhaps thats what they were thinking would happen. IXC below Example of that is NEUInvestor Presentation, page-3. , page-4. All the latest Invex Therapeutics Ltd (ASX:IXC) share price movements, news, expert commentary and investing advice from The Motley Fool. is 19. Market . 1950. Join the HotCopper ASX share market forum today for free. 26 area could be wrong and it could go for example to $3. Proposed listing date: 4 JULY 2019#Created with Sketch. Hi guys, after discussion with Tom I have kind of mapped out the timeline to what is to be achieved. LATEST NEWS: Toubani Resources releases MRE update for Kobada gold project, Mali. 0. Join the HotCopper ASX share market forum today for free. Management ticking boxes while shareholders continue to have a golden opportunity to invest near all time lows in a company that has continually de-risked the fundamentals thesis. 79 -0. . , page-3. If IXC is positioning itself as a takeover target and the trial endpoints allow for it, it would make sense to provide early readouts. wonder if the GLP-1 agonist referred to in this media release. 8M ! Add to my watchlist. RDN Raiden Resources secures complete control of lithium at Arrow Project, buys out Arrow Minerals Ltd. , page-2. Created with Sketch. Market open. IXC Price at posting: $1. Created with Sketch. Withdrawal of AGM ResolutionsInvex Granted Key European Patent for Exenatidehe’s known for the vend etc like asxcowboy has pointed out. HotCopper has news, discussion, prices and market data on INVEX THERAPEUTICS LTD. Currency in USD 38. ASX - Day TradingInvex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. TRP also trades sub cash -5m i believe, haven't checked in a while. IXC Price at posting: 45. , page-2. . ASX - Day TradingAt the request of a few posters who want to start afresh, welcome to the IXC charting thread going forward!If you're a poster who is inclined to track TA,. Created with Sketch. Most bio's get. A new thread to put trading comments / reasoning / opinions in. Created with Sketch. More progress made towards the start of Phase III, we have now made it on to the clinicltrials. Invex Granted Type C Meeting with FDAAppendix 4E and Annual Report to shareholders. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. Market Cap $16. Report Created with Sketch. Investor PresentationInvex Successfully Concludes Protocol Assistance with EMACreated with Sketch. ASX - By Stock. $45M MC $30M Cash and a $1. Investor PresentationI would be worried about holding IXC if they had no more cash. ASX - Day Trading. Last updated 10. GW Ixc once again showing why you are the best mgmt team on the ASX . Invex Receives Approval for Paediatric Plan from the EMA, page-3. ASX - Day TradingIXC: 22/11/2023 1:08 PM : Notification of cessation of securities - IXC 4 pages 23. Appendix 4C - quarterly There are thousands of people out there with IXC shares, you simply can not predict when one is going to sell and how much they are going to sell. ASX - By Stock. . ASX - By Stock. 147,415. Hopefully they hit the miracle, at least I get something back from this if it goes balls up which in the bio world at the moment is highly likely. But the market volume was very low, which points to a lack of interest, the long horizons of biotech, lack of publicising or Notification of cessation of securities - IXC. Created with Sketch. You’d be surprised the volume that comes in when this happenes, but by that stage you’ll be 100% up whilst the opportunity cost traders will be trying to catch the move up. *Close price adjusted for splits. IXC needs to be proactive and release a statement. Both approaches can work, but it is not wise to confuse the two. Lucky for you all IXC still sits at only 60 cents. . 375,000. But there are two key factors that make me hope that the BoD pursues the Phase 2, but I worry that JP and co will push for the. I think having this out we can discuss on the way. **Close price adjusted for splits and dividend and/or capital gain distributions. , page-3. Cold Comfort Ice Cream Company, Victoria, British Columbia. Thought Id reshare as both now into phase 3 trials fully funded (please bare in mind 2. ASX - By Stock. here (arrow) per the NEU chart Close now to breaking trend and establishing a more upper trend into results IMO IXC Price at posting: 40. 05. IXC Price at posting:. Ceasing to be a substantial holderAustralian finance news, stock quotes, currency information and blogsQuarterly Activities/Appendix 4C Cash Flow ReportInvex Granted European Patent for Exenatide in Hydrocephalus. Created with Sketch. , page-5. Jellyroll, arkangel, CD, balkanbroker to name a few have laid out some pretty compelling thesis' on where IXC will be heading. Latest Posts. boolish Jellyroll hey. . It certainly has been a hard few months for the biotech sector with PEB, NYR, NOX and now IXC all having prangs. ASX - By Stock. Hi All, I have decided to make an IXC broker data thread, as my PAR broker data thread was very well received. I think having this out we can discuss on the way. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. , page-4. com. For IXC I see the risk in one indication, comparatively lower TAM than others and different formulation for a week duration while phase II used daily. . Backed by Twiggy. ASX - By Stock. . Too many factors to make an educated appraisal of buyout pre-Phase 2 or post Phase 2. Charts. . Report to HotCopper and itll be the end of it, cheers. . IXC Price at posting: 37. The fact it recovered and closed about the 1. 1. Market . Results of MeetingInvex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. ASX - By Stock. Currency in USD 38. A new thread to put trading comments / reasoning / opinions in. ASX - By Stock. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. Created with Sketch. . ASX - Day Trading. Anyone buying now can carry to $5 and then sell a few prior to readout as insurance against losing everything in the coin flip. Daily bounced well off support and now slowly creeping upId like to see a range develop now between say 18 - 23 before next bit of news, page-517. 0¢ Sentiment: Buy Disclosure: Held. Andrew Forrest , or his entities have been involved with IXC since inception. Latest Posts. 1. 1950. . It was well aware of the claims made, released such information in the prospectus (and still had a hugely successful IPO), and would have done their due diligence before entering into any agreements with the University. ASX - By Stock. Created with Sketch. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-8. Slow and steady with IXC. ASX - Short Term Trading. Advertise on HotCopper. 19 Per share (Personal Estimate) vs MST Research report of $3. I find this very intriguing and positive that in last few weeks about 1. Login to your CommSec account to buy. 0 Great. Contrast that to data from Wales in 2017 which suggests that. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. Hopefully that placement overhang will be removed today tomorrow and the share price will catch up. Created with Sketch. Australia's largest stock trading and investment forum Australia's #1 stock forum Australia's #1 stock forumFound this article a while back although raises some decent points. 6million shares?, and if so is anyone worried about this, release date 29th. 0. . IXC below Example of that is NEU Investor Presentation, page-3. 76 (-1. Maybe more common that what people think, imagine once GPs start diagnosing it even better if a treatment is developed, Prevalence could increase 2 or times which ultimately increases. ASX - Day TradingA new thread to put trading comments / reasoning / opinions in. Learn how it impacts everything we do. Australian finance news, stock quotes, currency information and blogs0. 3¢. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. ASX - Day TradingAlthough with IXC fully cashed up it makes this fall irrational and the odd one out of alot of these small cap speccies that are death spiralling - aka, opportunity . Issue of Tranche 1 Placement Shares and Appendix 2A. . Good fundamental research starting points for IXC:Summary: IXC FactsheetMST Analyst Equity Research ReportFiftyOne Capital ReportPresentation - Tom Duthy. ASX - By Stock. Top 20 remains holding 58% compared to 58. The company can always acquire something new or do some capital returns. ASX - Day TradingCreated with Sketch. 69KBThis doesn't mean that IXC is doomed, just that things are more a gamble than an investment at the moment. 26 area could be wrong and it could go for example to $3. 31% more bullish than other Healthcare sector stocks. , page-6. Notification of cessation of securities - IXC. Share A few weeks ago in the lead up to the Phase 2 results invex included this slide on their slide deck - 'average 42 million increase in market cap after positive Phase 2 results'. Notice of Investor Call and Presentation, page-2. 20 to $7. 9 more clinical sites to be rapidly activated in a country with a growing incidence of IIH cases. 3¢. Market . The Phase III raise encompassed the costs for a go-it-alone reformulation strategy, with Bell Potter suggesting in a Q&A with IXC that they saved $5-6M in going with Peptron for their reformulation supply/manufacturing, alongside 12 months in time. 54am 24/11/2023 ? HotCopper has news, discussion, prices and market data on INCA MINERALS LIMITED. Notice of Quarterly Investor Call. , page-4. , page-3. 38 was the valuation MST gave IXC 9 months ago Considering we are now even further de-risked, getting to the end result, wonder what MST valuation would be now. Charts. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving. IXC Valuation Report MST. . pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. A new thread to put trading comments / reasoning / opinions in. 0¢ Sentiment: Buy Disclosure: Held. ASX - Day Trading. ASX. Although, IXC is trading about 3-4x lower than what I expect it to be. All IMO IXC Price at posting: 37. Met primary endpoints for phase 2 trials. ASX - Day Trading. Created with Sketch. . 91%) As of 03:35PM EST. , page-35. ASX - General. ASX - Day TradingChange in substantial holding. ASX - General. ASX - Short Term Trading. The IXC stock may trade low due to this wider macroeconomic issues, but the business itself is top 5% to its peers merely from the fact of having no future funding requirements and that if the trial is a success having close to immediate revenues and default alive status via Peptron manufacturing contract fulfilling demand on potential FDA. Created with Sketch. Market . Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical developmentNotice of Annual General Meeting/Proxy Form. ASX - Day Trading. Market . Created with Sketch. 3¢. Invex Receives Approval for Paediatric Plan from the EMA, page-2. When can we expect some update or. As thread states post your questions here and let’s start compiling a list. Just another way to saying that we've got Patient 1 out of 240. IXC Valuation Report MST. . , page-17. , page-2. . Im not expecting anything out of the ordinary apart from the fact thats its overdone and too undervalued at the stage its at. Created with Sketch. IXC (ASX) Ann: Trading Halt - HotCopper. ASX - General. . 5¢ Sentiment: Buy Disclosure: Held. Only took that large seller to sell, now liquidity has dried up and. The announcement was certainly a setback but we're not dead in. ASX - By Stock. Latest Posts ForumsHalf Yearly Report and AccountsLooks like people are starting to wake up here and realise how bloody cheap IXC is. View listing photos, review sales history, and use our detailed real estate filters to find the perfect place. 00 over the course of 2 years, and then doubled to $14 overnight on FDA approval. LoginJoin Now. 1950. Created with Sketch. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical developmentHREC and TGA Approval to Commence Phase 3 in AustraliaHi guys, after discussion with Tom I have kind of mapped out the timeline to what is to be achieved. ASX - Day TradingCreated with Sketch. 1. is there any news release, or SP increasing due to only the market showing interest, page-2. ASX - General. 5¢ INVEX THERAPEUTICS LTD - Discussion. Below is the broker data for IXC November to. Release Date: 20/03/23 08:11; Summary: German Approval for IIH EVOLVE Phase 3 Clinical Trial; Price Sensitive: Yes; Download Document 195. Created with Sketch. Although, IXC is trading about 3-4x lower than what I expect it to be for current stage ($100M-$125M MC aka $75-100M EV) Hi All, Having scrolled through the IXC forum for 18-24 months now, I have seen quite literally 200+ posts of charts discussing the stock price, and only. Created with Sketch. Charts. ASX - Short Term Trading. 1950. Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-2. Market . Trading HaltDCF Valuation: IXC Intrinsic Value of $6. 76 (-1. Latest Posts. Created with Sketch. Webinvest Pty Ltd<Olsb Unit A/C>. Created with Sketch. IXC on the other hand with nearer catalysts has already done its basing cycle Of course different stock different TAMS etc etc, probably why IMU is worth 640 mill MC and IXC 28 mill MC But again its why IXC is offering so much more in terms of value atm plus risk v reward All IMO of course, but yeh maybe some IMU investors pop across. Created with Sketch. Created with Sketch. . ASX - General. RAC went from 30 cents to $4 in the space of 5 months PAR went from 30 cents to $4 in the space of 1 and half years NEU went from $1. More. , page-188. , page-6. Charts. 0¢ Sentiment: Buy Disclosure: HeldHotCopper has news, discussion, prices and market data on GENESIS MINERALS LIMITED. ASX - Day TradingCreated with Sketch. ASX - By Stock. Andrew Forrest , or his entities have been involved with IXC since inception. ASX - Day TradingCreated with Sketch. 0. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. . Latest Posts. With a team of 68. . . pause in tradingHere we go! AU and UK sites activated for immediate recruitment. (IXC) - see HotCopper and other bloggers' predictions - TipRanks. 54pm 22/11/2023 ? HotCopper has news, discussion, prices and market data on INVEX THERAPEUTICS LTD. ASX - General. ASX - Day Trading. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. 31% more bullish than other Healthcare sector stocks. Commodities. 00% 21. Will management look for an early exit or are they wanting to take to market? Just came across IXC from another stock @JabraD posts on. Im not expecting anything out of the ordinary apart from the fact thats its overdone and too undervalued at the stage its at. ASX - By Stock. . Read in the announcement, has changed name and he has bought more ixc, page-2. Not sure what software this is but is there a way you can send the document itself, is a tad tough to read it with the photo you sent, if not all good, page-4. Charts. Created with Sketch. Created with Sketch. Spot on - filled the 1. Appendix 4C - quarterly* or having a go at doing so, page-30. 333334. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. Date of AGM and Closing Date for Director NominationsCD is on the money once again, page-195. . Join the HotCopper ASX share market. ASX - General. Plans & Pricing. Advertise. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. Created with Sketch. IXC is at base, so it’s just a matter of when it’ll leave base and start turning to the upside. ASX - Day TradingInitial FDA and EMA Advice on Presendin Development, page-2. Forums. Last updated 10. It was well aware of the claims made, released such information in the prospectus (and still had a hugely successful IPO), and would have done their due diligence before entering into any agreements with the University. 8,369 likes · 140 talking about this · 1,407 were here. ASX - Short Term Trading. Should jump back in Titans, was good having you on board as you know your stuff IXC Price at posting: 57. IAMIncome Asset Management to boost bond sales through partnership with Netwealth. See page-34.